Abstract
ObjectiveAlzheimer's disease (AD) is characterized by amyloid-beta (Aβ1-42) aggregation, oxidative stress, and neuronal loss, necessitating novel therapeutic agents to mitigate these pathological hallmarks.MethodThis study investigates the neuroprotective and antioxidant properties of newly synthesized borenium (compounds 1-4) and borinium (compounds 5-8) derivatives in an in vitro AD model using differentiated SH-SY5Y neuroblastoma cells exposed to Aβ1-42. Furthermore, automated Total Antioxidant Capacity assays were conducted using commercially available kits on culture media collected from cell cultures following 24 h of incubation. 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide and lactate dehydrogenase tests were done to determine the cytotoxicity of boron compounds after application to the exposed cell lines of Aβ1-42.ResultsIt was determined that the boron compounds applied to the cell lines at different concentrations did not show any neurotoxic effect at a concentration of 50 μM in 24 h of incubation. All boron compounds were determined to have antioxidant properties. It was found that the borinium compounds are much more neuroprotective than the borenium.ConclusionThese findings highlight the therapeutic potential of borenium and borinium compounds as neuroprotective and antioxidant agents for AD, warranting further mechanistic and in vivo studies.